» Articles » PMID: 31759250

PODXL1 Promotes Metastasis of the Pancreatic Ductal Adenocarcinoma by Activating the C5aR/C5a Axis from the Tumor Microenvironment

Overview
Journal Neoplasia
Publisher Elsevier
Specialty Oncology
Date 2019 Nov 24
PMID 31759250
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Pancreatic invasive ductal adenocarcinoma (PDAC) is a representative intractable malignancy under the current cancer therapies, and is considered a scirrhous carcinoma because it develops dense stroma. Both PODXL1, a member of CD34 family molecules, and C5aR, a critical cell motility inducer, have gained recent attention, as their expression was reported to correlate with poor prognosis for patients with diverse origins including PDAC; however, previous studies reported independently on their respective biological significance. Here we demonstrate that PODXL1 is essential for metastasis of PDAC cells through its specific interaction with C5aR. In vitro assay demonstrated that PODXL1 bound to C5aR, which stabilized C5aR protein and recruited it to cancer cell plasma membranes to receive C5a, an inflammatory chemoattractant factor. PODXL1 knockout in PDAC cells abrogated their metastatic property in vivo, emulating the liver metastatic mouse model treated with anti-C5a neutralizing antibody. In molecular studies, PODXL1 triggered EMT on PDAC cells in response to stimulation by C5a, corroborating PODXL1 involvement in PDAC cellular invasive properties via specific interaction with the C5aR/C5a axis. Confirming the molecular assays, histological examination showed coexpression of PODXL1 and C5aR at the invasive front of primary cancer nests as well as in liver metastatic foci of PDAC both in the mouse metastasis model and patient tissues. Hence, the novel direct interaction between PODXL1 and the C5aR/C5a axis may provide a better integrated understanding of PDAC biological characteristics including its tumor microenvironment factors.

Citing Articles

Spatial transcriptomic analysis of primary and metastatic pancreatic cancers highlights tumor microenvironmental heterogeneity.

Khaliq A, Rajamohan M, Saeed O, Mansouri K, Adil A, Zhang C Nat Genet. 2024; 56(11):2455-2465.

PMID: 39294496 DOI: 10.1038/s41588-024-01914-4.


Combining gemcitabine and MSC delivering soluble TRAIL to target pancreatic adenocarcinoma and its stroma.

Grisendi G, DallOra M, Casari G, Spattini G, Farshchian M, Melandri A Cell Rep Med. 2024; 5(8):101685.

PMID: 39168103 PMC: 11384958. DOI: 10.1016/j.xcrm.2024.101685.


Identification of molecular subtypes and a prognostic signature based on m6A/m5C/m1A-related genes in lung adenocarcinoma.

Zhang Y, Jia Q, Li F, Luo X, Wang Z, Wang X Sci Rep. 2024; 14(1):7543.

PMID: 38555384 PMC: 10981664. DOI: 10.1038/s41598-024-57910-5.


Blockade of C5a receptor unleashes tumor-associated macrophage antitumor response and enhances CXCL9-dependent CD8 T cell activity.

Luan X, Lei T, Fang J, Liu X, Fu H, Li Y Mol Ther. 2023; 32(2):469-489.

PMID: 38098230 PMC: 10861991. DOI: 10.1016/j.ymthe.2023.12.010.


Review and Application of Integrin Alpha v Beta 6 in the Diagnosis and Treatment of Cholangiocarcinoma and Pancreatic Ductal Adenocarcinoma.

Lian Y, Zeng S, Wen S, Zhao X, Fang C, Zeng N Technol Cancer Res Treat. 2023; 22:15330338231189399.

PMID: 37525872 PMC: 10395192. DOI: 10.1177/15330338231189399.


References
1.
Schopperle W, DeWolf W . The TRA-1-60 and TRA-1-81 human pluripotent stem cell markers are expressed on podocalyxin in embryonal carcinoma. Stem Cells. 2006; 25(3):723-30. DOI: 10.1634/stemcells.2005-0597. View

2.
Horvat R, Hovorka A, Dekan G, Poczewski H, Kerjaschki D . Endothelial cell membranes contain podocalyxin--the major sialoprotein of visceral glomerular epithelial cells. J Cell Biol. 1986; 102(2):484-91. PMC: 2114082. DOI: 10.1083/jcb.102.2.484. View

3.
Doyonnas R, Nielsen J, Chelliah S, Drew E, Hara T, Miyajima A . Podocalyxin is a CD34-related marker of murine hematopoietic stem cells and embryonic erythroid cells. Blood. 2005; 105(11):4170-8. DOI: 10.1182/blood-2004-10-4077. View

4.
Wada Y, Maeda Y, Kubo T, Kikuchi K, Eto M, Imamura T . C5a receptor expression is associated with poor prognosis in urothelial cell carcinoma patients treated with radical cystectomy or nephroureterectomy. Oncol Lett. 2016; 12(5):3995-4000. PMC: 5104221. DOI: 10.3892/ol.2016.5137. View

5.
Sakaguchi M, Watanabe M, Kinoshita R, Kaku H, Ueki H, Futami J . Dramatic increase in expression of a transgene by insertion of promoters downstream of the cargo gene. Mol Biotechnol. 2014; 56(7):621-30. PMC: 4067539. DOI: 10.1007/s12033-014-9738-0. View